Franseen needle in endobronchial ultrasound-guided transbronchial needle aspiration: a phase II prospective study.

IF 1.9 4区医学 Q3 ONCOLOGY

Japanese journal of clinical oncology Pub Date : 2024-09-04 DOI:10.1093/jjco/hyae077

Kohei Shikano, Jun Ikari, Takahiro Nakajima, Masayuki Ota, Yuki Shiko, Akira Naito, Mitsuhiro Abe, Takeshi Kawasaki, Jun-Ichiro Ikeda, Yoshihito Ozawa, Takuji Suzuki

{"title":"Franseen needle in endobronchial ultrasound-guided transbronchial needle aspiration: a phase II prospective study.","authors":"Kohei Shikano, Jun Ikari, Takahiro Nakajima, Masayuki Ota, Yuki Shiko, Akira Naito, Mitsuhiro Abe, Takeshi Kawasaki, Jun-Ichiro Ikeda, Yoshihito Ozawa, Takuji Suzuki","doi":"10.1093/jjco/hyae077","DOIUrl":null,"url":null,"abstract":"Background: Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) has been used to diagnose and stage lung cancer. Acquire™ Pulmonary and Expect™ Pulmonary dedicated EBUS-TBNA needles were introduced as the Franseen and Lancet needles, respectively. It is still unclear whether the Franseen or Lancet needles yield a higher quality specimen especially focusing on next-generation sequencing-based molecular testing.Methods: A single-center, prospective study performed at the Chiba University Hospital randomly assigned patients to two groups: Group A, wherein the first and second EBUS-TBNA were performed using Lancet and Franseen needles, respectively, and Group B, wherein the first and second EBUS-TBNA were performed using Franseen and Lancet needles, respectively. Each specimen was compared and analyzed pathologically. The primary outcome was the histological tissue area except blood clot and the cellularity of each sample. We also examined the success rate of molecular testing.Results: Twelve patients who underwent EBUS-TBNA between November 2022 and February 2023 were enrolled in this study. The tissue area of the specimens obtained by the Franseen and Lancet needles was 13.3 ± 6.4 mm2 and 10.6 ± 6.3 mm2, respectively (P = .355). The tumor cellularity in the specimens obtained using the Franseen and Lancet needles was 54.0 ± 30.3 and 46.2 ± 36.3%, respectively (P = .608). The success rate of molecular testing using the single-pass sample by Franseen needle was 85.7 and 57.1% by Lancet needle. No serious complications were reported.Conclusions: The Franseen needle tended to show a greater amount of specimen with higher tumor cellularity than the Lancet needle which may contribute higher success rate of molecular testing. Further studies must be conducted to validate the results of this study.Key findings: What is known and what is new? What is the implication, and what should change now?","PeriodicalId":14656,"journal":{"name":"Japanese journal of clinical oncology","volume":" ","pages":"1037-1044"},"PeriodicalIF":1.9000,"publicationDate":"2024-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11375049/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Japanese journal of clinical oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/jjco/hyae077","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) has been used to diagnose and stage lung cancer. Acquire™ Pulmonary and Expect™ Pulmonary dedicated EBUS-TBNA needles were introduced as the Franseen and Lancet needles, respectively. It is still unclear whether the Franseen or Lancet needles yield a higher quality specimen especially focusing on next-generation sequencing-based molecular testing.

Methods: A single-center, prospective study performed at the Chiba University Hospital randomly assigned patients to two groups: Group A, wherein the first and second EBUS-TBNA were performed using Lancet and Franseen needles, respectively, and Group B, wherein the first and second EBUS-TBNA were performed using Franseen and Lancet needles, respectively. Each specimen was compared and analyzed pathologically. The primary outcome was the histological tissue area except blood clot and the cellularity of each sample. We also examined the success rate of molecular testing.

Results: Twelve patients who underwent EBUS-TBNA between November 2022 and February 2023 were enrolled in this study. The tissue area of the specimens obtained by the Franseen and Lancet needles was 13.3 ± 6.4 mm2 and 10.6 ± 6.3 mm2, respectively (P = .355). The tumor cellularity in the specimens obtained using the Franseen and Lancet needles was 54.0 ± 30.3 and 46.2 ± 36.3%, respectively (P = .608). The success rate of molecular testing using the single-pass sample by Franseen needle was 85.7 and 57.1% by Lancet needle. No serious complications were reported.

Conclusions: The Franseen needle tended to show a greater amount of specimen with higher tumor cellularity than the Lancet needle which may contribute higher success rate of molecular testing. Further studies must be conducted to validate the results of this study.

Key findings: What is known and what is new? What is the implication, and what should change now?

查看原文本刊更多论文

支气管内超声引导下经支气管针吸术中的 Franseen 针：II 期前瞻性研究。

背景：支气管内超声引导下经支气管针吸术（EBUS-TBNA）已被用于肺癌的诊断和分期。Acquire™ Pulmonary 和 Expect™ Pulmonary 专用 EBUS-TBNA 针分别作为 Franseen 针和 Lancet 针问世。目前还不清楚 Franseen 针和 Lancet 针是否能产生更高质量的标本，尤其是基于下一代测序的分子检测：在千叶大学医院进行的一项单中心前瞻性研究将患者随机分为两组：A组分别使用Lancet针和Franseen针进行第一次和第二次EBUS-TBNA检查，B组分别使用Franseen针和Lancet针进行第一次和第二次EBUS-TBNA检查。对每个标本进行比较和病理分析。主要结果是每个样本的组织学组织面积（血块除外）和细胞度。我们还检查了分子检测的成功率：本研究共纳入了 2022 年 11 月至 2023 年 2 月期间接受 EBUS-TBNA 治疗的 12 例患者。弗兰森针和柳叶刀针获得的标本组织面积分别为（13.3 ± 6.4）平方毫米和（10.6 ± 6.3）平方毫米（P = .355）。使用弗朗森针和柳叶刀针获得的标本的肿瘤细胞度分别为 54.0 ± 30.3% 和 46.2 ± 36.3%（P = .608）。使用 Franseen 针进行单次样本分子检测的成功率为 85.7%，使用 Lancet 针的成功率为 57.1%。无严重并发症报告：与柳叶刀针相比，Franseen针往往能显示出更多肿瘤细胞度更高的标本，这可能有助于提高分子检测的成功率。必须开展进一步研究来验证本研究的结果：哪些是已知的，哪些是新的？有什么影响，现在应该做些什么改变？

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Japanese journal of clinical oncology 医学-肿瘤学

CiteScore

3.70

自引率

8.30%

发文量

177

审稿时长

3-8 weeks

期刊介绍： Japanese Journal of Clinical Oncology is a multidisciplinary journal for clinical oncologists which strives to publish high quality manuscripts addressing medical oncology, clinical trials, radiology, surgery, basic research, and palliative care. The journal aims to contribute to the world"s scientific community with special attention to the area of clinical oncology and the Asian region. JJCO publishes various articles types including: ・Original Articles ・Case Reports ・Clinical Trial Notes ・Cancer Genetics Reports ・Epidemiology Notes ・Technical Notes ・Short Communications ・Letters to the Editors ・Solicited Reviews